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Abstract
Background: Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials.
An important barrier to further increased use is a lack of understanding about which additional resources are
required to conduct a high-quality adaptive clinical trial, compared to a traditional fixed design.
The Costing Adaptive Trials (CAT) project investigated which additional resources may be required to support
adaptive trials.
Methods: We conducted a mock costing exercise amongst seven Clinical Trials Units (CTUs) in the UK. Five
scenarios were developed, derived from funded clinical trials, where a non-adaptive version and an adaptive
version were described. Each scenario represented a different type of adaptive design.
CTU staff were asked to provide the costs and staff time they estimated would be needed to support the trial,
categorised into specified areas (e.g. statistics, data management, trial management). This was calculated separately
for the non-adaptive and adaptive version of the trial, allowing paired comparisons.
Interviews with 10 CTU staff who had completed the costing exercise were conducted by qualitative researchers to
explore reasons for similarities and differences.
Results: Estimated resources associated with conducting an adaptive trial were always (moderately) higher than for
the non-adaptive equivalent. The median increase was between 2 and 4% for all scenarios, except for sample size
re-estimation which was 26.5% (as the adaptive design could lead to a lengthened study period). The highest
increase was for statistical staff, with lower increases for data management and trial management staff.
The percentage increase in resources varied across different CTUs. The interviews identified possible explanations
for differences, including (1) experience in adaptive trials, (2) the complexity of the non-adaptive and adaptive
design, and (3) the extent of non-trial specific core infrastructure funding the CTU had.
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Conclusions: This work sheds light on additional resources required to adequately support a high-quality adaptive
trial. The percentage increase in costs for supporting an adaptive trial was generally modest and should not be a
barrier to adaptive designs being cost-effective to use in practice.
Informed by the results of this research, guidance for investigators and funders will be developed on appropriately
resourcing adaptive trials.
Keywords: Adaptive designs, Adaptive clinical trials, Clinical trials, Efficiency, Resource requirements, Trial
coordination
Background
Clinical trials are vital for demonstrating safety, efficacy,
and effectiveness of interventions aimed at improving
patient health. The cost of conducting trials is high and
is increasing; it is a major factor behind the increasing
costs of drug development [1] and evaluation of non-
pharmacological interventions [2]. Because of this, there
has been a big drive towards developing trial methods
that can increase operational and statistical efficiency.
One important class of methods is adaptive trial de-
signs [3]. An adaptive design, according to the adaptive
CONSORT extension [4], ‘offers pre-planned opportun-
ities to use accumulating trial data to modify aspects of
an ongoing trial while preserving the validity and integ-
rity of that trial’. There are many types of adaptive trial
designs that can be used for different purposes. Gener-
ally, they have one or more of the following objectives
compared to traditional trial designs: (1) improving the
power of the trial, (2) reducing the average sample size
used and trial duration for a target level of power, and
(3) improving outcomes of patients who are enrolled on
the trial [5].
The use of adaptive designs has been increasing in re-
cent years [6–8] although it still remains low when com-
pared to traditional trial designs. Some barriers to
increased use have already been identified [9–11]). These
include lack of awareness of their purpose and potential,
expertise, training, and availability of easy-to-use soft-
ware for implementation, alongside a paucity of experi-
ences in their delivery. Although there is still more to
do, these barriers are being steadily addressed, especially
for less complex adaptive methods. Adaptive designs
have been widely and successfully used in trials of
COVID-19 prevention and treatment [12], which will
likely lead to further demand for their use.
One important area that has received less attention re-
lates to the cost and resource needed to implement
adaptive designs, which generally require interim ana-
lyses to be conducted quickly and to a high level of qual-
ity. Additionally, trials using adaptive designs are usually
more complex and may require more effort to set up,
manage, monitor, analyse, and close.
The complexities associated with adaptive designs may
mean they require additional resource to develop and
conduct. This might be difficult to quantify upfront (e.g.
when developing a grant application) without having
substantial knowledge and experience of developing and
running trials using an adaptive design from start to fin-
ish. This issue is further exacerbated by lack of transpar-
ent data about the costs of different aspects of running
trials [13]. Previous research has been published on re-
source needs for trials generally [14–16], but none fo-
cused on additional requirements for adaptive designs. A
need for further research and guidance on this issue was
identified within the MRC-NIHR Trials Methodology
Research Partnership Adaptive Designs Working Group.
This led to an application for funding that formed a na-
tional project team to investigate the resource require-
ments for adaptive trials and develop best-practice
guidance for various stakeholders.
The objectives were:
1) To estimate the perceived additional (financial and
staffing) resources needed to conduct trials using
adaptive designs through conducting a mock
costing exercise of several types of trial scenarios
2) To investigate reasons for differences between non-
adaptive and adaptive trials through qualitative
research
3) To provide best-practice guidance on what add-
itional resources should be included in funding
applications for trials using adaptive designs
This paper presents the research results of the CAT
project, including the mock costing exercise project and
the qualitative research (objectives 1 and 2). A separate
paper will focus on providing guidance that arose from
the research (objective 3).
Methods
Development of mock costing scenarios
A subgroup of the CAT team developed five trial scenar-
ios for different Clinical Trials Units (CTUs) to provide
costs for. These five scenarios were based on real and
funded trials, although with some changes made to avoid
any comparison to the CTU costs of the original trial.
In each scenario, a non-adaptive version of the trial
was provided, with a protocol synopsis containing a
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summary of the trial’s PICO (Participants, Interven-
tion(s), Comparator, Outcomes). The scenario also out-
lined a summary of the adaptive design proposed, with
the rationale and implications it would have on the
design.
Table 1 provides an overview of the different scenar-
ios. A full description of each scenario is provided in
Additional file 1.
Resource and cost data requested
A spreadsheet (Additional file 2) was provided to CTUs
which asked for information on the resources required
to undertake the costing of each scenario. This was split
into the following: (1) pre-award the resources needed
to develop the application to the point of the grant start-
ing, (2) post-award staff resources that would be re-
quired to deliver the trial, and (3) post-award non-staff
costs required to deliver the trial once the grant had
started. Typically, pre-award resource needs are covered
by the institution (e.g. using existing core infrastructure
funding), with post-award costs mostly covered by the
grant funder.
For staff resource, information was requested on staff
type, co-applicant status, grade, contract type, whether
the post was underpinned by central funding, the per-
centage of full-time equivalent (FTE) the staff member
would be working on the project (either averaged over
the length of the trial, or at different levels during the
trial), total months on trial, total salary cost (including
direct employment-related costs e.g. employer taxes and
pension contributions), full economic costs (FEC)
charged, and any additional indirect employment-related
costs (e.g. recruitment costs). For non-staff resource,
suggested cost items were listed including stationery,
travel (trial oversight committees, site initiation visits,
monitoring, closedown of centres), project meeting costs
(launch and investigator meetings), teleconferencing
fees, clinical data management and randomisation sys-
tem fees, Medicines and Healthcare products Regulatory
Agency (MHRA) fees (including amendments), comput-
ing costs (including specialist statistical software), staff
training, patient and public involvement (PPI), dissemin-
ation (including open-access publication costs), data
sharing, and post project costs (e.g. data archiving and
anonymisation). Each CTU could also add any additional
costs not suggested.
Staff resource and non-staff costs were collected for
both the non-adaptive and adaptive versions of each sce-
nario. Guidance was given to each participating CTU as
comments within the spreadsheet and a separate guid-
ance document (see Additional file 1). If CTU staff
undertaking the costing exercise had queries, they were
offered the opportunity to email the subgroup of the
CAT team.
After receiving the completed costings, any queries
were emailed directly to the person who completed
them at the participating CTU. The majority of these
queries were resolved; for the very few minor unresolved
queries, assumptions were made based on the other
information provided by that CTU.
Participating Clinical Trials Units
In the initial grant application, some of the co-applicants
were associated with CTUs. Additional CTUs were
Table 1 Brief overview of each scenario used in the mock costing exercise
Scenario/non-adaptive design Adaptive design and features
1. A two-arm parallel-group randomised controlled trial assessing the
addition of biomarker-testing to an existing early warning score in the
management of patients with suspected sepsis in the emergency
department
Group-sequential designa including a single interim analysis with futility
stopping after half of patients have had primary outcome observed.
2. A phase 2b randomised dose-finding study of JAK1 inhibitor for pa-
tients with active rheumatoid arthritis
Adaptive dose-finding design that has a single interim analysis after half
of patients have primary outcome observed. The dose allocation used in
the second stage is set according to an optimal allocation from a three-
parameter emax model fitted to stage 1 patient outcomes.
3. A multi-arm parallel-group phase 3 trial comparing regimens for treat-
ing intermediate and high-risk oropharyngeal cancer
Multi-arm multi-stage design with two interim analyses (2 years and 4
years into a 5-year recruitment period) that allows early stopping of ex-
perimental arms for lack of benefit. The trial continues to full enrolment
unless all experimental arms stop early.
4. A multi-arm parallel-group trial assessing clinical efficacy and cost-
effectiveness of earlier treatment of ovarian hyper-stimulation syndrome
(OHSS)
Adaptive umbrella design, allowing early stopping of arms within the two
patient subgroups. In the early OHSS subgroup, a MAMS design is used
with one interim analysis allowing stopping for lack of benefit; in the late
OHSS subgroup, a group-sequential design with early stopping for lack of
benefit is used.
5. Randomised two-arm parallel-group trial of the efficacy of nicotinic
acid derivative (NAD) for treatment of fatigue in mitochondrial disease
Sample size re-assessment design that will use blinded estimate of the
pooled standard deviation to re-estimate the sample size required. If this
is above a specified level, the trial will stop early for futility.
aGroup-sequential designs are not always considered an example of an adaptive design but were included in the definition within this project as they also involve
a pre-specified interim analysis of outcome data
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invited through an email sent to Directors of all 53 UK
Clinical Research Collaboration (UKCRC)-registered
CTUs, describing the project, in November 2019. All
materials required for conducting the costing were sent
out in January 2020, with a request to send back com-
pleted costings by March 2020.
Analysis methods
Due to the large variation in the grades of staff at different
institutions, it was decided to summarise requested staff
resource using the number of ‘FTE-years’ without refer-
ence to grade or cost. The FTE-year for a staff post is the
number of years that a post is funded on the grant multi-
plied by the average percentage of FTE. As an example, a
staff member funded at 50% FTE for 4 years would con-
tribute 2 FTE-years to the total staff resource requested.
FTEs were analysed as total, as well as by categories of staff
by type. The main categories were statistics, data manage-
ment, and trial management. Other categories included pro-
gramming, administration, quality assurance, senior
management/operations, data entry, and researcher; how-
ever, these were inconsistently used across CTUs and have
not been included as individual staff groups in this manu-
script (although they do contribute to the total resource cal-
culated). Non-staff costs are presented as a total.
Staff FTE-years and non-staff costs are presented as a
percentage change between the non-adaptive and adap-
tive design, and as a relative change for the adaptive de-
sign compared to the median non-adaptive design
figure, for each scenario and CTU. This was after discus-
sion with the project group and was implemented to en-
sure anonymity of the CTUs involved and due to
commercial confidentiality. Statistical analysis was de-
scriptive and the percentage change data was sum-
marised as a median and range. Relative change for each
scenario was summarised using spaghetti plots. A spa-
ghetti plot has a separate line for each individual CTU
that returned a costing for the scenario, linking the esti-
mated resources for the non-adaptive and adaptive ver-
sion of the scenario. Plots were created using the
ggplot2 package [17] in R [18].
Qualitative methods
Participants who undertook the costing exercise were in-
vited to interview and all were interviewed via videocon-
ference and audio recorded. A semi-structured topic
guide was developed from previous work on costing tri-
als [14] and at an investigators’ meeting in July 2020 fol-
lowing the costing exercise. This included questions
relating to the differences across CTUs and explored
local costing procedures and reasons for differences in
costs between the adaptive and non-adaptive scenarios.
Qualitative interviews were transcribed verbatim and
coded in NVivo (Windows, version 1.3). The National
Centre for Social Research ‘Framework’ approach [19]
(familiarisation, identifying a thematic framework, index-
ing, charting, and mapping and interpretation) was used
for analysis. Themes were derived inductively from read-
ing the transcripts.
The results were presented and discussed at an investi-
gators’ meeting in January 2021.
Funding and ethical approval
CAT was funded by the NIHR Efficient Studies Funding
panel (Reference: NIHR130351). The funder played no
role in the design, conduct, or reporting of the research.
The project received an ethical waiver by Newcastle Uni-
versity’s ethics committee due to it not involving pa-
tients. Consent was obtained for all participants who
took part in the interviews.
Results
Mock costing exercise results
A total of 10 CTUs expressed willingness to take part in
the mock costing exercise. Of these, seven contributed
at least one costing, with three providing a costing for
all five scenarios; uptake and drop out was impacted by
the COVID-19 pandemic, which substantially increased
workload within CTUs from March 2020.
A costing for both the non-adaptive and adaptive ver-
sions of the scenario was always given. Each scenario
had costings from at least five CTUs (Table 2).
Table 3 summarises the changes in staff resource that
were requested for adaptive designs. This is split by sce-
nario and by the main staff categories. Figures 1, 2, 3, 4,
and 5 show the range in FTE-years for each scenario.
Across all scenarios, resources increased for the adap-
tive design compared to the non-adaptive design. The
median increase in staff resource was modest (2–4%) for
all adaptive designs other than sample size re-
estimation. However, this larger increase was driven by
the increase in the length of the time needed for the
adaptive trial. As discussed in the qualitative results sec-
tion, CTU resource needs were calculated assuming the
maximum project length would be achieved. Even for
scenarios with low median increase, there was consider-
able variation across CTUs in this increase; this was
explored further in the qualitative results section.
The resource needs for individual categories of staff
demonstrate that across the scenarios, statistical resource
generally increased the most, followed by data manage-
ment and then trial management for the adaptive designs
compared to their non-adaptive scenario. There was con-
sensus across all CTUs, for all scenarios, that statistical re-
source should be increased for adaptive designs. The
median statistics FTE-year increase for scenarios 1–4 was
between 9 and 17%, with a larger increase for the sample
size re-estimation design (scenario 5).
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There was inconsistency on whether trial management
resource should be increased for all scenarios, except the
group sequential design where all CTUs increased the
resource.
For data management, all CTUs increased resource for
the group-sequential design, MAMS, and sample size re-
estimation designs, but there were divergent responses
for the phase 2b dose response and the umbrella study.
Changes in non-staff costs for each scenario are shown
in panel (b) of Figs. 1, 2, 3, 4, and 5. All CTUs increased
non-staff costs for the sample size re-estimation, but
there was inconsistency for the other scenarios. Exam-
ples of non-staff costs that increased were randomisation
and clinical data management system costs, patient and
public involvement costs, and MHRA fees.
Qualitative results
All seven CTUs that provided at least one costing also
took part in an interview. Staff who did the costing exer-
cise were interviewed individually or in pairs where they
had worked together on the costing exercise. Eight inter-
views took place with 10 individuals (mean length 40
min; range 33–55 min). All interviews were conducted
by KB, with two observed by JH. Two of the interviewees
were known to the interviewer prior to the interview;
the interviewer has a role in costing in a CTU and took
part in the mock costing exercise.
Participant background
Interviewees were experienced in costing trials, with
variation in their experience of costing adaptive designs.
Individuals with more experience in adaptive designs
tended to work on trials in oncology or rare diseases
where these designs are more common.
[M]y main experiences around adaptive designs,
and that’s becoming more common in cancer and I
think it’s probably becoming more common in, in
all areas now. 011
There was some difference in opinion about what an
adaptive trial is and whether all scenarios were truly
adaptive. This has been noted in other research [10].
So the scenario one I wouldn’t consider it adap-
tive…. Scenario two is a dose finding study, … it’s
Table 2 Summary of which CTU completed the costing exercise for each scenario
Scenario
1. Group sequential design 2. Phase 2b dose response 3. Phase 3 MAMS 4. Umbrella study 5. Sample size re-estimation
CTU 1 ✓ ✓ ✓ ✓ ✓
2 ✓ ✓ ✓ ✓
3 ✓
4 ✓ ✓ ✓ ✓
5 ✓ ✓ ✓ ✓ ✓
6 ✓ ✓ ✓ ✓ ✓
7 ✓ ✓ ✓
CTU clinical trials unit, MAMS multi-arm multi-stage; each CTU has been allocated an anonymous number
Table 3 Summary of the percentage increase in total FTE-years, FTE-years for statistics, data management and trial management,
and non-staff costs between the adaptive over the non-adaptive version of each scenario






% increase in data
management FTE-years,
median (range)
% increase in trial
management FTE-years,
median (range)










2.2% (0.7%, 17.5%) 13.4% (4.6%, 21.9%) 0.0% (0.0%, 6.6%) 0.0% (0.0%, 20.8%) 4.2% (0.0%, 8.2%)
3. Phase 3
MAMS (n=5)
3.0% (1.3%, 7.9%) 16.7% (4.7%, 26.0%) 9.6% (0.0%, 19.8%) 0.0% (0.0%, 14.2%) 0.8% (0.0%, 5.3%)
4. Umbrella
study (n=5)




26.5% (0.8%, 38.9%) 36.8% (2.9%, 56.3%) 28.75% (2.9%, 39.3%) 22.2% (0.0%, 34.6%) 13.5% (0.8%, 19.0%)
FTE full-time equivalent, MAMS multi-arm multi-stage
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not an adaptive trial. Scenario three, I think I would
say is adaptive. Scenario four, I don’t consider adap-
tive. And scenario five, I don’t consider adaptive. So
there’s only one scenario I actually thought was an
adaptive trial. 010
Costing exercise
Interviewees generally used a similar process for
costing non-adaptive and adaptive designs, with
some differences in who was involved in the
costing.
Fig. 1 a FTE-years relative to non-adaptive median (set to 100) for scenario 1. b Total non-staff cost relative to non-adaptive median (set to 100)
for scenario 1
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Fig. 2 a FTE-years relative to non-adaptive median (set to 100) for scenario 2. b Total non-staff cost relative to non-adaptive median (set to 100)
for scenario 2
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Fig. 3 a FTE-years relative to non-adaptive median (set to 100) for scenario 3. b Total non-staff cost relative to non-adaptive median (set to 100)
for scenario 3
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Fig. 4 a FTE-years relative to non-adaptive median (set to 100) for scenario 4. b Total non-staff cost relative to non-adaptive median (set to 100)
for scenario 4
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Fig. 5 a FTE-years relative to non-adaptive median (set to 100) for scenario 5. b Total non-staff cost relative to non-adaptive median (set to 100)
for scenario 5
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The more complex a trial is, the more discussion
you need to have with your colleagues to under-
stand what it actually means for them. 014
Most CTUs had a template or model that they worked
from and would use this to guide resource needs for all
design types. A few CTUs had costing guidance in
addition or instead of a template, and two interviewees
said they did not use a template.
[W]e’ve got our costing model set-up, so almost,
you know, when a trial comes in, its construction,
whether it’s adaptive or not, it shouldn’t change the
way we cost something. 011
In the adaptive versions of the trials, people considered
the consequences of each adaptation during the costing
process, whether they used a template or not.
I don’t use a proforma, it’s really just sitting down
and working out what the different complexities are
…. And that’s where sitting down with the Statisti-
cians and the Pharmacists to work out what the im-
pact of each of those adaptations... 010
I would say the approach would be really broadly
the same. I think for a standard costing and for an
adaptive costing you’re always thinking ok what,
what might make this trial deviate from (yeah) the,
the sort of norm, the expected and trying to think
about any costs that might be incurred because of
that. 015
In cases where the adaptive trial design would have a
variable duration (e.g. group sequential design or sample
size re-assessment), all interviewees costed for the
‘worst-case scenario’ to ensure the CTUs could deliver
the whole trial. Most interviewees discussed the impact
of not including enough resource in the costs, and that
under-costing a study can adversely impact CTUs and
their staff.
[O]ne of the huge benefits [of adaptive designs] is
that you may be able to do things much more cost
efficiently, because the study may stop early for
whatever reason. And the difficulty is, from a cost-
ing perspective, you have to assume that at every
step of an adaptation, the more costly and longer
option is what will be selected. 010
Because of this, interviewees said they would present
the highest cost to a funder but some added they might
present a range of costs in the justification of costs in a
finding application to show what the adaptive design
would cost if it stopped at any of the pre-planned stages.
[I]f I was doing it for a funder then I might present
both cases, the maximum (yeah) and what happens
if it’s not the maximum, so sample size, re-
estimation was an example where I provided two
different adaptive costings depending on the mini-
mum and maximum sample size required. 003
Resource needed
All interviewees increased statistics resource in the adap-
tive design scenarios, and the majority also increased
data management (or related roles). Some increased trial
management time, but not for every scenario. Increases
in costs were mainly due to an increase in staff resource.
Actually, the methodologist role, sort of senior per-
son we didn’t increase however, increased time for
trial manager, senior trial manager, data manager
most definitely and the trial administrator. 005
Sample size re-estimation increased the FTE-years and
non-staff costs more on average than other scenarios, but
this was due to the maximum project length increasing.
So, where you have a sample size re-estimation, [the
funder doesn’t] necessarily want you to … go back
for extra money. 010
The lack of experience with some designs and there-
fore the consequence of interim analyses may have led
to an underestimate of the work involved.
[W]e don’t know if it did come to.. the interim ana-
lysis and we did have to drop an arm would that
suddenly turn out to be .. much more work than
we’d thought about for everybody else. 001
Statistics resource
Statistics resource (i.e. FTE-years) was always increased
to undertake the interim analyses, and sometimes in-
creased due to a higher workload during the develop-
ment of the protocol and the statistical analysis plan.
So I think typically I would’ve put more time in for
the design part of it… design went from two weeks
to four weeks for the first scenario… Statistical ana-
lysis plan I put in two extra weeks for that to ac-
count for any interim analysis plan… and actually
doing an interim analysis I put four weeks for that
and probably put a slight extra bit for the analysis…
the other tasks remained the same. 003
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Some considered additional roles in relation to the
need for an unblinded and a blinded statistician for the
adaptive designs.
[A]re you going to need additional junior statisti-
cians? Because are you going to have to have one
that’s blinded and one unblinded? ... Because again,
in most studies we’ll have a senior and junior statis-
tician, but the moment you get to adaptive trials,
you’re often thinking, ‘well actually, we need an-
other person involved’ and then your costs are being
pushed up. But they’re always so different. You can’t
really standardise any of the process. You end up
having to sit down one by one and figure it out. 010
Some interviewees increased the FTE-years of the stat-
istician (and other staff) across the project, and some
added additional resource at times of interim analysis
and discussed how this might influence planning within
the CTU.
We tend to run a model where even though we
know there’s peaks and troughs within a trial, we do
tend to flat line and try and make sure that work-
load is balanced across a range of projects at differ-
ent stages… We tend to find [that] the easiest way
to manage both staff and projects. 005
Trial management resource
CTUs that increased trial management time, usually by in-
creasing the FTE across the trial, did so to cover increased
complexity of the protocol and set-up tasks, the potential
for increased protocol amendments, data cleaning, site
monitoring, and other activity around interim analyses.
There was variation between CTUs and scenarios on
whether trial management resource should be increased.
But for, say, a trial manager, you don’t know if any
one of those time points might result in a protocol
amendment. The easier way to do it is just uplift it
a little bit and smooth it, and as when you need that
resource you manage it within your manpower
within the unit. 014
When trial management resource was not increased, it
was thought the trial manager could undertake the additional
tasks required for the adaptive design within the FTE-years
that they had been allocated for the non-adaptive design.
[D]epending on an adaptation, it may mean more
frequent, or an adaptation may mean less fre-
quent visits to sites. But if you've always costed
at the maximum.... it shouldn't change your cost-
ing. 010
Data management/programmer resource
CTUs increased data management or related resource to
undertake changes to the randomisation system or the
database during the trial, or for increased activity around
interim analyses, e.g. for data cleaning, database lock,
and reporting.
[I]f you are dropping an arm for example [the ran-
domisation system] needs to be adapted after that
interim analysis. So you need … the time for the
data manager to undertake that work. 005
CTUs that did not increase data management resource
(or increased it by a small amount only) either thought
the work would fit in with the resource already allocated,
or tended to be those that were more experienced in
making adaptations during their trials and therefore had
systems set up to accommodate these changes, such as
units experienced in oncology trials.
[I]f you’ve built the database in a way that reflects
an adaptive design, you shouldn’t need to fiddle
around with it too much whether it’s switched on
or switched off. So a CTU that has got experience
of this sort of design… the requirements shouldn’t
be that different. 011
All CTUs increased data management resource for
group-sequential design, MAMS, and sample size re-
estimation but there was disagreement for the phase 2b
dose response and the umbrella study.
I don’t think I’ve changed the duration on the sec-
ond one [phase 2b]. So I don’t think the costs chan-
ged on that. 010
I think the umbrella or the MAMS design, where I
just chose to uplift all of the job roles and that’s due
to an element of uncertainty. So, some of the sce-
narios you can really focus in on what the tasks will
be and what the consequences of the decision will
be. Others, there’s so much uncertainty that I feel
the only way to be able to deal with the variety of
options is to uplift all FTEs. 014
Seniority or experience of staff for ADs
The majority of interviewees said they did not change
seniority between adaptive and non-adaptive scenarios
for any of the staff groups.
[W]e haven’t gone for a higher statistician… no
we’ve kept the same grades that we would normally
just with more time 001
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And actually there is less to do sometimes within
stats about seniority and more to do with experi-
ence in a particular design... So we tend to find …
because it’s an adaptive design always need a senior.
005
In some cases, seniority was thought to be important
in the complexity of the design or adaptation and may
have varied between scenarios rather than between
adaptive and non-adaptive versions.
In that case, I would put a higher-grade trial man-
ager on it, because I would pre-empt that you need
that level of expertise into the future. 014
A few interviewees increased the seniority of the statis-
tician when costing the adaptive design compared to the
non-adaptive design, due to the particular expertise or
experience required.
[S]tatistician roles are kind of [less experienced
grade], [more experienced grade] mostly and so I
think I would be assigning more of the [more expe-
rienced grade] to the sort of key roles in the adap-
tive trials because of the impact on the design. 015
Other costs
There were other cost implications for adaptive designs
discussed in the interviews. Drug manufacture was not
included in the scenarios, but this would need to be con-
sidered for drug trials.
[T]he fact that if that now means a manufacturing
step, you may have a two month, three month delay
before you can actually implement that adaptation,
because if that requires a decision about drug
manufacturing to not be made until that interim,
then they often won't have built in the timelines
that are needed. 010
Other costs identified as important by at least one
interviewee in costing adaptive designs were resources
for additional monitoring visits and oversight meetings
(including Patient and Public Involvement) due to ex-
tended timelines and interim analyses; resource needed
for writing and publication fees for additional publica-
tions; and additional training and computer equipment.
In some CTUs, randomisation systems and database
costs incurred non-staff costs rather than staff costs,
which increased for an adaptive design.
Some of the others, so, the umbrella study, MAMS
design, I would potentially expect a longer set-up
period. They are, in my experience, much harder to
set up – the information you require during set-up
is a lot higher. So, I would – the complexity of the
study drives the set-up times. 014
All CTUs increased non-staff costs for the sample size
re-estimation, but there was disagreement for the other
scenarios.
[Y]ou wouldn’t have put any large differences for
sort of data capture systems or randomisation sys-
tems cause yeah, they’re all in-house… 015
[F]or the non-staff costs, I think they changed a bit
more, because part of the formula we’ve got in our
costing is based on sample size, and you know, the
length of time, so how many meetings and stuff you
have, so that obviously changes. 011
Uncertainty and complexity
Those experienced in adaptive designs commented on
the driver for costs relating to complexity and uncer-
tainty rather than just being a trial that has pre-planned
adaptations. This complexity or uncertainty also
accounted for differences in increases between the non-
adaptive and adaptive scenarios within a CTU.
What we do is very complex even if it’s not adaptive
and so we think about the complexity and try to
make sure that we’ve got the right level of resource
in that initial costing. 012
CTU funding
CTUs had a range of different funding structures, lead-
ing to differences in the number of core (non-trial spe-
cific) funded staff, and other aspects of running a trial.
Funding for CTUs included infrastructure from univer-
sities, public sector organisations (e.g. NIHR), and char-
ities, which impacted on costs required for each
individual trial.
[H]aving that kind of core infrastructure to lead on
development activity is really important; we are so
lucky to have it and I know that not all CTUs do.
012
[O]bviously our costs would be internally consistent
for the adaptive and the non-adaptive but just in
terms of the overall level of costings sort of reflect
that unsupported environment in relative terms
compared to, you know, having these other inputs.
015
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Discussion
Adaptive designs can provide considerable benefit to
clinical trials; however, staff and non-staff resources re-
quired to support them have not been previously exam-
ined. This study, which used both quantitative and
qualitative methods to explore the resource needs for a
range of adaptive trial designs with academic CTUs in
the UK, found that adaptive trials are generally thought
to require more staff and non-staff resources than non-
adaptive trials.
Resource needs in the mock costing exercise were gen-
erally included at the highest that would be needed, the
so-called worst case scenario. This was to avoid, where
possible, the requirement to return to the funder for
additional funding, or the need for an academic institu-
tion to cover unfunded trial resource needs. This repre-
sents a potential limitation of most funders in the UK,
where a single project length and cost is typically re-
quested prior to the project being funded. Only one
CTU described providing funders with multiple costs for
different scenarios. This is illustrated by the sample size
re-estimation scenario resulting in the highest increase
in resources due to the potential for a substantial in-
crease in project length if the adaptive design increases
the sample size.
Those who had experience of working with adaptive
trial designs in oncology and rare diseases were likely to
be those with the most experience of the design, devel-
opment, and delivery of adaptive trials. These units gen-
erally increased resources less for adaptive designs due
to their increased familiarity with these designs that are
more normalised in these disease areas.
Resources were consistently increased for statistical
staff across every scenario. This reflected additional work
required for more complex protocols and statistical ana-
lysis plans (perhaps including a simulation study to in-
form the design of the trial), alongside the time needed
to undertake the interim analyses. There was wider vari-
ability in the need for additional staff resource beyond
statistics. The data and trial management time was not
increased for some scenarios; however, the wide ranges
indicate that this is not consistent between units, and
may be a reflection of the ‘worst case scenario’ costing
and the complexity of the non-adaptive design in each
scenario.
The complexity of the non-adaptive design in each
scenario may also explain the variability between scenar-
ios. As an example, the non-adaptive dose response (sce-
nario 2) and umbrella design (scenario 4) were seen as
complex even without an adaptive design. The non-
adaptive umbrella design is effectively two trials run
under the same protocol, so in itself provides advantages
over running two separate trials. It should also be noted
that not all scenarios were costed by every CTU, which
may additionally explain some differences in variability
between scenarios.
The approach to costings differed between, and in
some cases within, units depending on the staff involved
in costing. The two main approaches involved using in-
dividual tasks to generate the associated FTE, and ex-
perience based. Most trials units chose to flatten the
percentage FTE to give a single figure across the trial.
Differences in contexts and processes across CTUs mean
it is unlikely the variability in additional resources re-
quired for adaptive designs would ever completely
disappear.
The requirements for extra non-staff costs related
mostly to additional monitoring visits and database and
randomisation system costs. There is great variation
across CTUs in the systems used; those that had systems
that had been developed in-house did not require add-
itional costs to implement the required adaptive ele-
ments to the trials (although they may still have needed
additional staff resource).
It is clear that adaptive designs are often more com-
plex to design and deliver than their non-adaptive coun-
terparts. The uncertainty about whether trials will, for
example, require an increased sample size, increased
time, or other pre-planned changes may raise their per-
ceived financial risk level for CTUs that are less experi-
enced in their design and delivery.
One notable type of adaptive design that was not thor-
oughly considered is Response Adaptive Randomisation
(RAR), in which allocation probabilities to treatment
arms are changed according to patient outcomes ob-
served. One area that RAR has been used in is multi-
arm and umbrella trials, such as I-SPY2 [20]. Scenario 2
involved changing the randomisation allocation to differ-
ent doses at an interim analysis and therefore has some
similarities to RAR. However, designs like I-SPY2 as-
sume continual change in allocation after each patient’s
outcome is observed, whereas scenario 2’s adaptive de-
sign included only one change. Interestingly, scenario 2
had the highest change in median non-staff costs (except
for sample size re-assessment), due to the change in ran-
domisation required. Having continual change in ran-
domisation probabilities during the trial would likely
increase these costs further.
We would highlight that the median increase in cost
compares favourably against the increase in efficiency
that some adaptive designs can provide. As an example,
even a two-stage group-sequential design can reduce the
average sample size used by up to 35% [21] with more
interims reducing this further (see e.g. [22]). This max-
imum gain is impacted by the choice of design, the true
treatment effect, and the delay in how long it takes to as-
sess the primary outcome [23, 24]. Other adaptive de-
signs can increase the average power of the trial,
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improve patient benefit, or ensure the trial is robust to
uncertainties as the design stage. It is difficult to quan-
tify these advantages provided to directly compare to the
increased cost, and more research is required on this.
Limitations
Although this research has provided useful information,
there are several limitations. The resource exercise fo-
cussed on CTU resources and did not explore other re-
search costs such as resources for drug/intervention
supply, or other methodological groups that may be in-
volved in a trial, for example health economists or re-
searchers using qualitative methods. The results are
derived from seven CTUs in the UK which ranged from
moderate size to amongst the largest in the UK. Five of
the seven CTUs had researchers involved in the CAT
grant application, although in only one case was a grant
co-applicant the staff member who did any costings. An-
ecdotally, CTUs that had not previously run an adaptive
trial were less likely to take part from the 53 invited to
participate. Some CTU staff who took part were open
that they had less experience in adaptive designs and
may not fully understand the implications on resources
required.
Theoretical scenarios were provided without the wider
context of the full application, and without opportunity
for refinement of resource needs based on discussion
and feedback inherent to trial development. There was
recognition in the interviews that final resource needs
would involve a process of discussion and refinement.
Without repeating the exercise or engaging in re-
running the exercise including a discussion element, it
will not be known what impact this may have had on
the resources included. The scenarios covered trials of
differing durations, making it difficult to draw direct
comparisons between scenarios. The costing spreadsheet
provided (Additional file 2) may have limited the scope
of providing resource estimates, although was not re-
ported as a barrier in the interviews.
The CTUs included in the project all operate autono-
mously, as such the operational structures differ, includ-
ing with differing job roles and titles. Where possible,
job roles were combined for the analysis, to enable com-
parison and protect the anonymity of units and individ-
uals contributing to the resourcing exercise. This may
lead to subtlety in some roles being lost (e.g. a statistical
programmer role could have some data management du-
ties as well as statistical).
Further research and guidance
This is the first piece of research to systematically gather
and analyse prospective data on resourcing clinical trials
utilising an adaptive design. Whilst we have seen large
variance in our sample, we have also identified a
consistent and clear need for (typically modest) add-
itional resource, most notably in statistical support. We
would recommend that a similar exercise is conducted
again in 3–5 years as the field continues to evolve, to en-
sure that trialists, investigators, and funders understand
the resource needs of adaptive trials, and to refine the
guidance as the efficiencies of the designs become fur-
ther embedded in a wider number of therapeutic areas
and trials units. This exercise could include methodo-
logical disciplines not included in this exercise, such as
health economists and qualitative researchers (who are
not typically based in CTUs). The exercise could also
benefit from improved reporting of adaptive trials that
would result from the adaptive designs CONSORT ex-
tension [4].
In conjunction with this paper summarising the re-
search, we are developing a guidance paper for re-
searchers who wish to resource an adaptive trial. This
will also include a template costing tool representing all
the tasks required for an adaptive trial. It will also con-
tain recommendations for funders of trials that may
allow more transparent, informative costings for adap-
tive trials that would ensure adaptive designs can con-
tinue to increase in use.
As mentioned earlier, further research to better quan-
tify the benefits of adaptive designs and allow equating it
to the increased costs identified here would be useful.
There is also a need for further development of trials
methods that could be used to reduce the additional
cost, for example to do interim analyses more efficiently.
Such methods could be implemented and investigated in
trials using a study within a trial (SWAT) to ensure any
positive and negative impacts of the method are
measured.
Conclusions
Adaptive designs provide convincing advantages in many
situations. Findings from this research indicate that
adaptive trials may require more staff and non-staff re-
sources than non-adaptive trials, at least in the ‘worst
case scenario’. Further research to examine how to
weigh-up the advantages against the additional resource
would help ensure that adaptive designs are used when
they are likely to provide benefit. Additional research
that could help reduce the gap in resources required be-
tween non-adaptive and adaptive trials would help in-
crease the number of situations when the latter are cost-
effective.
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